Literature DB >> 3090051

Recovery patterns of rat hemopoietic stem cells between pulse doses of 7,12-dimethylbenz(a)anthracene (DMBA) applied in a leukemogenic regimen.

I Fohlmeister, O Hohentanner, A Porr.   

Abstract

Male Wistar rats received repeated pulse doses of 7,12-dimethylbenz(a)anthracene (DMBA), known to elicit myelodysplasia followed by acute, mostly erythroblastic, leukemia at 10-day intervals. The recovery of spleen colony forming hemopoietic stem cells (CFU-s) surviving the cytocidal action of DMBA was examined between pulses. Recovery after a pulse of 35 mg/kg body weight varied with the organ source of the CFU-s (femoral bone marrow or spleen) and the number of preceding DMBA pulses. After a single DMBA pulse bone marrow CFU-s initially recovered faster than reported for normal bone marrow CFU-s transplanted into chemically conditioned rats. But recovery was followed by regeneration arrest. Population doubling times of marrow CFU-s increased with the number of DMBA pulses. Recovery of splenic CFU-s was slower after a single DMBA pulse than reported for normal spleen CFU-s transplanted into chemically conditioned rats. The CFU-s population doubling times were not significantly different after a single or five DMBA pulses. After three pulses, however, recovery of splenic CFU-s was exceedingly slow until day 5 and subsequently accelerated, but was still slower than after one or five pulses. In the spleen CFU-s recovery was always accompanied by regeneration of total cell numbers with a preference for erythroid regeneration. In the bone marrow this was the case after three DMBA pulses only.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3090051     DOI: 10.1007/bf00389239

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  21 in total

1.  X-ray and alkylating agents alter differentntiation of surviving hematopoietic stem cells.

Authors:  S Hellman; H E Grate
Journal:  Blood       Date:  1971-08       Impact factor: 22.113

2.  Specific vulnerability of the largest telocentric chromosome of rat bone marrow cells to 7,12-dimethylbenz[a]anthracene.

Authors:  T Sugiyama
Journal:  J Natl Cancer Inst       Date:  1971-12       Impact factor: 13.506

3.  Biologic studies on 7,12-dimethylbenz(alpha) anthracene-induced rat leukemia with special reference to the specific chromosomal abnormalities.

Authors:  T Sugiyama; Y Kurita; Y Nishizuka
Journal:  Cancer Res       Date:  1969-05       Impact factor: 12.701

Review 4.  Ultraviolet mutagenesis and inducible DNA repair in Escherichia coli.

Authors:  E M Witkin
Journal:  Bacteriol Rev       Date:  1976-12

5.  S-phase resistance of rat hematopoietic stem cells to 7,12-dimethylbenz(a)anthracene cytocide and its implications for leukemia development.

Authors:  I Fohlmeister; O Hohentanner; A Porr
Journal:  Cancer Res       Date:  1984-09       Impact factor: 12.701

6.  Effect of daily administration of cytotoxic drugs on the erythroid and granulocytic repopulating ability of rat bone marrow.

Authors:  G R Standen; N M Blackett
Journal:  Acta Haematol       Date:  1980       Impact factor: 2.195

7.  The relationship between the spleen colony-forming cell and the haemopoietic stem cell.

Authors:  R Schofield
Journal:  Blood Cells       Date:  1978

8.  [Experimental induction of preleukemic myelopoietic dysplasias by dimethylbenz (a) anthrazene (DMBA). A rat model for investigation of human "preleukemia" (author's transl)].

Authors:  I Fohlmeister; R Fischer; H E Schaefer
Journal:  Pathol Res Pract       Date:  1981-05       Impact factor: 3.250

Review 9.  Myelodysplastic syndromes: pathogenesis, functional abnormalities, and clinical implications.

Authors:  A Jacobs
Journal:  J Clin Pathol       Date:  1985-11       Impact factor: 3.411

10.  Chemotherapy of autochthonous leukemias induced by 7,12-dimethylbenz(a)anthracene in Long Evans rats.

Authors:  W J Zeller; M Berger; D Schmähl
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.